ERNA
Price
$1.11
Change
-$0.02 (-1.77%)
Updated
Sep 25, 03:25 PM (EDT)
Capitalization
8.67M
XCUR
Price
$4.25
Change
+$0.74 (+21.08%)
Updated
Sep 24 closing price
Capitalization
26.85M
Interact to see
Advertisement

ERNA vs XCUR

Header iconERNA vs XCUR Comparison
Open Charts ERNA vs XCURBanner chart's image
Ernexa Therapeutics
Price$1.11
Change-$0.02 (-1.77%)
Volume$200
Capitalization8.67M
Exicure
Price$4.25
Change+$0.74 (+21.08%)
Volume$46.06K
Capitalization26.85M
ERNA vs XCUR Comparison Chart in %
Loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERNA vs. XCUR commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERNA is a Hold and XCUR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (ERNA: $1.13 vs. XCUR: $4.25)
Brand notoriety: ERNA and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERNA: 145% vs. XCUR: 96%
Market capitalization -- ERNA: $8.67M vs. XCUR: $26.85M
ERNA [@Biotechnology] is valued at $8.67M. XCUR’s [@Biotechnology] market capitalization is $26.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERNA’s FA Score shows that 1 FA rating(s) are green whileXCUR’s FA Score has 0 green FA rating(s).

  • ERNA’s FA Score: 1 green, 4 red.
  • XCUR’s FA Score: 0 green, 5 red.
According to our system of comparison, both ERNA and XCUR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERNA’s TA Score shows that 5 TA indicator(s) are bullish while XCUR’s TA Score has 6 bullish TA indicator(s).

  • ERNA’s TA Score: 5 bullish, 3 bearish.
  • XCUR’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XCUR is a better buy in the short-term than ERNA.

Price Growth

ERNA (@Biotechnology) experienced а -4.24% price change this week, while XCUR (@Biotechnology) price change was +19.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.83%. For the same industry, the average monthly price growth was +8.56%, and the average quarterly price growth was +51.82%.

Industries' Descriptions

@Biotechnology (+0.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XCUR($26.9M) has a higher market cap than ERNA($8.67M). XCUR YTD gains are higher at: -68.910 vs. ERNA (-74.376). XCUR has higher annual earnings (EBITDA): -12.42M vs. ERNA (-31.63M). XCUR has more cash in the bank: 7.86M vs. ERNA (4.32M). XCUR has less debt than ERNA: XCUR (476K) vs ERNA (593K). ERNA has higher revenues than XCUR: ERNA (488K) vs XCUR (0).
ERNAXCURERNA / XCUR
Capitalization8.67M26.9M32%
EBITDA-31.63M-12.42M255%
Gain YTD-74.376-68.910108%
P/E RatioN/A0.19-
Revenue488K0-
Total Cash4.32M7.86M55%
Total Debt593K476K125%
FUNDAMENTALS RATINGS
ERNA vs XCUR: Fundamental Ratings
ERNA
XCUR
OUTLOOK RATING
1..100
150
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9696
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (23) in the Medical Specialties industry is in the same range as XCUR (35) in the null industry. This means that ERNA’s stock grew similarly to XCUR’s over the last 12 months.

ERNA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XCUR (100) in the null industry. This means that ERNA’s stock grew similarly to XCUR’s over the last 12 months.

XCUR's SMR Rating (99) in the null industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that XCUR’s stock grew similarly to ERNA’s over the last 12 months.

XCUR's Price Growth Rating (96) in the null industry is in the same range as ERNA (96) in the Medical Specialties industry. This means that XCUR’s stock grew similarly to ERNA’s over the last 12 months.

XCUR's P/E Growth Rating (100) in the null industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that XCUR’s stock grew similarly to ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ERNAXCUR
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FOLD8.350.19
+2.33%
Amicus Therapeutics
FNF59.830.58
+0.98%
Fidelity National Financial
SCKT1.04N/A
N/A
Socket Mobile
SHBI16.98-0.06
-0.35%
Shore Bancshares
IDN5.54-0.08
-1.42%
Intellicheck

ERNA and

Correlation & Price change

A.I.dvisor tells us that ERNA and ATOS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ERNA and ATOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-6.61%
ATOS - ERNA
28%
Poorly correlated
+0.32%
RNTX - ERNA
28%
Poorly correlated
+6.25%
BDTX - ERNA
26%
Poorly correlated
+2.84%
BRTX - ERNA
25%
Poorly correlated
N/A
VSTM - ERNA
25%
Poorly correlated
-6.31%
More

XCUR and

Correlation & Price change

A.I.dvisor tells us that XCUR and VSTM have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XCUR and VSTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+21.08%
VSTM - XCUR
28%
Poorly correlated
-6.31%
AMGXF - XCUR
27%
Poorly correlated
N/A
NBY - XCUR
25%
Poorly correlated
+0.93%
ERNA - XCUR
23%
Poorly correlated
-6.61%
FBRX - XCUR
23%
Poorly correlated
-5.42%
More